Key result
Mydicar (AAV1-expressing SERCA2a) gene therapy failed in the phase IIb CUPID2 trial for heart failure.
Answers are grounded in this paper and cite their sources.
The failure of the phase IIb CUPID2 trial highlights the ongoing challenges in translating SERCA2a-targeted gene therapy for heart failure into clinical practice.
Gene therapy for heart failure hit another bump on the road to clinical translation with the announcement by Celladon that its lead product Mydicar'adeno-associated viral vector 1 (AAV1)-expressing sarcoplasmic reticulum calcium ATPase (SERCA2a)'had failed in the phase IIb CUPID2 trial.1 SERCA2a's role in heart failure was validated in the 1990s but proved to be an elusive target for therapeutic intervention using traditional drug discovery methods. It is well established that SERCA2a, which is critical to calcium homeostasis in the myocardium, is downregulated in failing heart, making it an important target for therapy.
No takes yet. Share an insight, caveat, or question.
Seppo Ylä‐Herttuala (2015) conducted an editorial in Heart failure. Mydicar (AAV1-expressing SERCA2a) was evaluated. Mydicar (AAV1-expressing SERCA2a) gene therapy failed in the phase IIb CUPID2 trial for heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: